Research Article
Laboratory Investigation (2009) 89, 833–839; doi:10.1038/labinvest.2009.35; published online 27 April 2009
Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice
Hirohisa Takano1,2,5, Ken-ichiro Inoue1,5, Akinori Shimada3, Hiroyuki Sato4, Rie Yanagisawa1 and Toshikazu Yoshikawa2
- 1Division of Environmental Health Sciences, National Institute for Environmental Studies, Tsukuba, Japan
- 2Department of Gastroenterology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
- 3Department of Veterinary Pathology, Faculty of Agriculture, Tottori University, Tottori, Japan
- 4Research Center, Mochida Pharmaceutical Company Ltd., Shizuoka, Japan
Correspondence: Dr K-i Inoue, MD, PhD, Division of Environmental Health Sciences, National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba 305-8506, Japan. E-mail: inoue.kenichirou@nies.go.jp
5These authors contributed equally to this work.
Received 29 August 2008; Revised 10 November 2008; Accepted 21 November 2008; Published online 27 April 2009.
Abstract
Urinary trypsin inhibitor (UTI), a serine protease inhibitor, has been widely used for patients with inflammatory disorders including disseminated intravascular coagulation, shock, and pancreatitis in Japan. Our recent studies using UTI-null (-/-) mice have shown that UTI protects against systemic inflammatory responses and acute lung injury. However, the role of UTI in liver injury has not been elucidated. This study determined the contribution of UTI to liver injury and coagulatory disturbance induced by lipopolysaccharide and D-galactosamine (LPS/D-GalN) using UTI (-/-) and wild-type (WT) mice. LPS/D-GalN treatment caused severe liver injury characterized by neutrophilic inflammation, hemorrhagic change, necrosis, and apoptosis, which was more prominent in UTI (-/-) than in WT mice. In both genotypes of mice, LPS/D-GalN challenge caused elevations of aspartate amino-transferase and alanine amino-transferase, prolongation of the prothrombin and activated partial thromboplastin time, and decreases in fibrinogen and platelet counts, as compared with vehicle challenge. These changes, however, were significantly greater in UTI (-/-) than in WT mice. Circulatory levels of tumor necrosis factor (TNF)-
(P<0.05) and interferon (IFN)-
were also greater in UTI (-/-) than in WT mice after LPS/D-GalN challenge. These results suggest that UTI protects against severe liver injury and subsequent coagulatory disturbance induced by LPS/D-GalN, which was mediated, at least partly, through the suppression of TNF-
production along with its antiprotease activity.
Keywords:
urinary trypsin inhibitor, lipopolysaccharide, D-Galactosamine, liver injury, disseminated intravascular coagulation
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
XIAP discriminates between type I and type II FAS-induced apoptosis
Nature Letters to Editor (20 Aug 2009)
An unusual cause of neonatal coagulopathy and liver disease
Journal of Perinatology Correspondence
Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation
Nature Letters to Editor (30 Apr 2009)
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
Nature Letters to Editor (23 Nov 1995)
Nature Medicine Article (01 Nov 2001)
D-galactosamine in mice&showall=research" target="_new">See all 8 matches for Research

